Shareholders Approve Option Repricing and Increased Equity Pool

summarizeSummary

Coherus Oncology shareholders approved the repricing of underwater stock options and an increase in the equity incentive plan, both of which carry negative implications for existing shareholders due to potential dilution.

check_boxKey Events

• Option Repricing Approved

  Shareholders narrowly approved the reduction in the exercise price of certain outstanding stock options (45,996,610 FOR vs 45,362,110 AGAINST). This finalizes the outcome of a proposal previously disclosed in proxy filings, and is generally viewed negatively as it increases the likelihood of future dilution.

• Equity Incentive Plan Expanded

  An increase in the number of shares reserved for issuance under the Amended and Restated 2014 Equity Incentive Award Plan was approved (59,507,788 FOR vs 24,853,379 AGAINST), raising the potential for future share dilution.

• Director Elections Confirmed

  Dennis M. Lanfear and Mats L. Wahlström were elected as Class III directors to hold office until the 2029 annual meeting.

• Auditor Ratified

  Ernst & Young LLP was ratified as the independent registered public accounting firm for fiscal year 2026.

auto_awesomeAnalysis

Coherus Oncology's shareholders approved two key proposals at its Annual Meeting: the repricing of certain outstanding stock options and an increase in shares reserved for the equity incentive plan. The option repricing, which passed by a narrow margin, is generally viewed negatively as it increases the likelihood of future dilution and can reduce management's incentive to drive stock price appreciation. The expansion of the equity plan further increases the potential for future share dilution, following recent capital raises.